Hexagon Bio Stock
HealthTechLooking to sell Hexagon Bio stock or options?
Hexagon Bio has developed a synthetic biology platform that leverages data science to explore genomes for small molecule inhibitors targeting specific proteins. This platform integrates genomics, synthetic biology, and automation to uncover evolutionarily refined compounds and their protein targets directly from fungal genomes. By tapping into the global metagenome, Hexagon Bio aims to identify new medicinal compounds, facilitating the development of innovative treatments to enhance patient care.
SoftBank Investment Advisers, Nextech Invest, Trancos Venture, LeFrak, Luma Bio-IT Management, Sherpalo Ventures, Casdin Capital, ATEL Capital Group, CPP Investments, bpd partners, Julia Hong, The Column Group, 8VC, Two Sigma Ventures.